major achievements and summary · major achievements and summary . publications. top 3 papers based...

of 26

CURRICULUM VITAE

Date 07/01/2020

NAME Louise Elizabeth PURTON QUALIFICATIONS B.Sc. (Hons), PhD CONTACT DETAILS

Email [email protected] Ph (03) 9231 2504

ORCID ID : 0000-0001-6593-3168 CURRENT APPOINTMENTS 2019-current Professor, Department of Medicine at St. Vincent’s Hospital, The University of Melbourne 2019-current Honorary Professorial Fellow, Department of Medicine at St. Vincent’s Hospital, The

University of Melbourne 2008-current Laboratory Head, St. Vincent’s Institute of Medical Research

Major Achievements and Summary

PUBLICATIONS

Top 3 papers based on Journal Impact Factor

1. Hawkins ED, Duarte D, Akinduro O, Khorshed RA, Passaro D, Nowicka M, Straszkowski L, Scott MK, Rothery S, Ruivo N, Foster K, Waibel M, Johnstone RW, Harrison SJ, Westerman DA, Quach H, Gribben J, Robinson MD§, Purton LE§, Bonnet D§, Lo Celso C. T-cell acute leukaemia exhibits dynamic interactions with bone marrow microenvironments. Nature 2016, 538:518-522. § Robinson, Purton and Bonnet are co-second last authors. (IF= 40, citations= 49) 2. Walkley CR, Shea JM, Sims NA, Purton LE, Orkin SH. Rb regulates interactions between hematopoietic stem cells and their bone marrow microenvironment. Cell 2007, 129:1081-1095. (IF= 30, citations= 272) 3. Walkley CR, Olsen GH, Dworkin S, Fabb SA, Swann J, McArthur GA, Westmoreland SV, Chambon P, Scadden DT, Purton LE. A microenvironment-induced myeloproliferative syndrome caused by retinoic acid receptor γ deficiency. Cell 2007, 129:1097-1110. Walkley and Olsen are equal first authors. IF= 30, citations= 313) Top 3 papers based on number of citations 1. Walkley CR, Olsen GH, Dworkin S, Fabb SA, Swann J, McArthur GA, Westmoreland SV, Chambon P, Scadden DT, Purton LE. A microenvironment-induced myeloproliferative syndrome caused by retinoic acid receptor γ deficiency. Cell 2007, 129:1097-1110. Walkley and Olsen are equal first authors. 313 citations (Scopus, 5/11/18) 2. Walkley CR, Shea JM, Sims NA, Purton LE, Orkin SH. Rb regulates interactions between hematopoietic stem cells and their bone marrow microenvironment. Cell 2007, 129:1081-1095. 272 citations (Scopus, 5/11/18). 3. Varnum-Finney B, Purton LE, Yu M, Brashem-Stein C, Flowers D, Staats S, Moore KA, Le Roux I, Mann R, Gray G, Artavanis-Tsakonas S, Bernstein ID. The Notch ligand, Jagged-1, influences the development of primitive hematopoietic precursor cells. Blood 1998; 91:4084-4091. 282 citations (Scopus, 5/11/18).

of 26

Leadership Past leadership achievements 2011-2019 Honorary Principal Fellow, Department of Medicine, The University of Melbourne 2011-2019 Associate Professor, Department of Medicine, The University of Melbourne 2011-2019 Founder and Member, St. Vincent’s Institute of Medical Research Career Development

Committee 2010-2019 Associate Director, St. Vincent’s Institute of Medical Research (I voluntarily resigned from this position) 2009- 2019 Student Co-ordinator, St. Vincent’s Institute (I voluntarily resigned from this position) 2014-2016 Member, Awards Committee, ISEH (comprising two consecutive terms). 2010-2013 Member, Board of Directors, International Society for Experimental Hematology (ISEH) 2012-2013 Member, Nominating Committee, ISEH Present leadership achievements 2017-2020 Member, American Society for Hematology (ASH) Scientific Committee on Stem Cells and

Regenerative Medicine 2015- current Member, Standing Research Subcommittee, Cancer Council of Victoria 2014- current Member, Executive Committee overseeing the New Directions in Leukaemia Research

biannual conference 2014- current Member, Faculty of Medicine, Dentistry and Health Sciences Graduate Research

Committee, The University of Melbourne 2010- current Member, St. Vincent’s Academic Centre (Eastern Hill Precinct) Research Training

Committee, The University of Melbourne 2008- current Laboratory Head, St. Vincent’s Institute of Medical Research Research (One line summary for each key research theme) The regulation of haematopoietic stem cell self-renewal by retinoic acid receptors. Extrinsic regulation of haematopoiesis by the bone marrow microenvironment. The use of mouse models of myelodysplastic syndromes (MDS) to understand MDS and identify better therapies for MDS. The use of advanced imaging technologies to study blood cell diseases using patient bone marrow biopsies. Major External Collaborations International:

Dr Cristina Lo Celso, Imperial College, London. Project: Investigating the effects of leukaemia on bone marrow microenvironments.

A/Prof Joy Wu, Stanford University, Stanford, USA. Project: Investigating the effects of osteoblast lineage cells on haematopoiesis.

Prof Pierre Chambon, IGBMC, Strasbourg, France. Project: The regulation of haematopoietic stem cell self-renewal by retinoic acid receptors.

Prof Lorraine Gudas, Joan and Sanford I. Weill Medical College of Cornell University, New York, USA. Project: The roles of Hoxa1 in the regulation of haematopoiesis.

National: A/Prof Carl Walkley, SVI. Project: Modeling myelodysplastic syndromes in mice to identify better therapies.

Dr Meaghan Wall, Department of Medicine, Monash Health, Monash University. Project: Modeling myelodysplastic syndromes in mice to identify better therapies.

A/Prof Hang Quach, St. Vincent’s Hospital, Melbourne. Project: The use of advanced imaging technologies to study blood cell diseases using patient bone marrow biopsies.

Prof David Ritchie, Royal Melbourne Hospital, Melbourne. Projects: Extrinsic regulation of haematopoiesis by the bone marrow microenvironment and identifying better therapies for MDS.

Prof John Pimanda, UNSW, Sydney. Projects: Regulation of haematopoiesis and identifying better therapies

of 26

for myelodysplastic syndromes.

Prof Harshal Nandurkar, ACBD, Monash University, Melbourne. Project: Roles of two oncogenes in myeloproliferative diseases.

A/Prof Edwin Hawkins, WEHI, Melbourne. Project: Investigating the effects of leukaemia on bone marrow microenvironments.

A/Prof Andrew Murphy, Baker IDI, Melbourne. Project: Extrinsic regulation of haematopoiesis by the bone marrow microenvironment.

Education (List role in undergraduate, postgraduate, non-medical educational activities) 2019 Initiated and co-ordinated a video interview with the Pulitzer prize-winning author, Dr

Siddhartha Mukherjee for the Cancer in Society subject, which is part of the University of Melbourne/Victorian Cancer Comprehensive Centre’s (VCCC) Master of Cancer Sciences program.

2018 Invited seminar, WEHI postgraduate students seminar series 2018 Invited seminar, Victorian Cancer Comprehensive Centre (VCCC) Comprehensive Cancer

PhD Program seminar series. 2015 Invited seminar, WEHI postgraduate students seminar series 2014- current Member, Faculty of Medicine, Dentistry and Health Sciences Research Training Committee 2010- current Member, St. Vincent’s Academic Centre Research Training Committee 2001-2004 Member, Peter MacCallum Cancer Centre PhD supervisory committee 1991-1994 Demonstrator in practical Physiology to students undertaking Medicine, Science and

Optometry degrees at The University of Melbourne, Australia. Guest (teaching) lectures 2019 I helped to organise and co-hosted (with Associate Professor Kylie Mason) an interview with

the Pulitzer prize-winning author and medical researcher, Associate Professor Siddhartha Mukherjee, which was filmed for the VCCC/University of Melbourne’s Masters of Cancer Sciences program, Cancer in Society subject.

2016-current Guest lecturer to students enrolled in the EDUC20069 Deafness and Communication subject at The University of Melbourne. In this half hour presentation I discuss my experiences as a hearing impaired person.

2013- current Guest Lecturer to 1st year Masters of Clinical Audiology Students enrolled at The University of Melbourne. In this half hour presentation I discuss my experiences as a hearing impaired person. In 2018 I presented to the students twice, pre- and post- cochlear implant.

Professional Service (For example government committees, journal editorial boards, College roles) Committees: 2018 Appointed to NHMRC GRP (withdrawn due to my cochlear implant proceeding in August

2018). 2015- Member, Standing Research Subcommittee, Cancer Council Victoria 2014- Member, Faculty of Medicine, Dentistry and Health Sciences Graduate Research

Committee, The University of Melbourne 2012 Member, NHMRC Grant Review Panel (GRP) 2010- Member, St. Vincent’s Academic Centre (Eastern Hill Precinct) Research Training

Committee, Department of Medicine, The University of Melbourne 2008-2015 Member, NHMRC Training Fellowships Grant Review Committee (Panel Chair in 2015) Journal Editorial Boards: 2020- current Experimental Hematology (appointed Associate Editor January 2020) 2018- current StemJournal (New journal established by the Harvard Stem Cell Institute soft launched in

late 2018 and officially launched in February 2019) (Associate Editor 2019-) 2017- current Experimental Hematology 2016- current Scientific Reports 2014- current PLoS One 2012-2015 F1000Research

of 26

2012-2014 Leukemia 2009-2015 Member, Faculty of 1000 Medicine, Hematopoiesis section International Recognition International recognition for my research: My research has pioneered studies showing that vitamin A enhances HSC self-renewal and that the receptors for vitamin A (retinoic acid receptors or RARs), have different roles in regulating haematopoiesis. I am recognised as an expert in this field in both the haematopoiesis and retinoid research fields, and I am also attracting international recognition for my research exploring the roles of the RARs in mesenchymal-derived cells. This research has led to invited international speaker presentations at conferences including FASEB Retinoids (2010- I was the only Australian invited to speak at this conference) and the upcoming annual meeting of the International Society for Experimental Hematology (ISEH, 2019). My research in this field has led to a clinical trial in the USA exploring the use of RAR-specific ligands to treat blood cell diseases. I am also recognised internationally for my research investigating roles of the bone marrow microenvironment in regulating normal and diseased haematopoiesis. My two Cell papers in 2007 showed that the bone marrow microenvironment could contribute to the initiation and sustainment of blood cell diseases. These landmark studies received widespread international media attention (press and online) and opened up a new field of investigation in bone marrow microenvironment research. I have received numerous international speaker invitations for my bone marrow microenvironment research, recent invitations including Keystone Hematopoiesis (2015, I was the only Australian invited speaker), ISEH (2015) and the upcoming annual meeting of the International Society of Cell and Gene Therapy in Melbourne (June 2019). International leadership roles: I was appointed to the Board of Directors of ISEH (2010-2013) and I have served on a number of committees for ISEH. I am a current member of the American Society of Hematology (ASH) Scientific Committee on Stem Cells and Regenerative Medicine. ASH is the largest international society in haematology research, having more than 17,000 members spanning over 100 countries. As a committee member, my role is to contribute to the development of the scientific program at the annual meeting, participate in identifying and nominating outstanding haematologists for the ASH Honorific awards, participate in ASH advocacy activities and contribute to policies and guidelines related to haematology. I am also an advocate for equal opportunity. When I was a member of the ISEH Awards committee I successfully lobbied for the eligibility criteria of the McCulloch and Till Award (awarded to an early-mid-career scientist within 15 years of becoming an independent investigator) to include allowances for career disruptions such as maternity leave or significant illness. As a member of ASH’s Scientific Committee on Stem Cells and Regenerative Medicine I have approached the Director of Awards and Diversity at ASH (Patricia Frustace) to likewise modify the conditions for the William Dameshek Prize (given to an outstanding investigator in the haematology field who is under the age of 50) to allow additional years based on the nature of the career disruptions of potential awardees. CV in detail FELLOWSHIPS AND MEMBERSHIPS 2010- current Member of the Australasian Society for Stem Cell Research 2010- 2016 Member of the Australian and New Zealand Bone and Mineral Society 2004- current Member of the International Society for Stem Cell Research 2002- current Member of the American Society for Hematology UNDERGRADUATE AND POSTGRADUATE DEGREES (Include dates obtained and thesis title if relevant) 1995 PhD, Department of Physiology, The University of Melbourne, supervisor Dr Neil Williams.

Thesis title: “Characterisation studies of the stromal cell types present in bone marrow.” 1990 B.Sc. (Hons), Department of Physiology, The University of Melbourne, supervisor Dr Neil

Williams. Thesis title: “The role of the endothelium as a sensor of platelet mass.” AWARDS / SCHOLARSHIPS 2016 SVI Foundation Award for outstanding contributions to St. Vincent’s Institute of Medical

Research. 2011-2015 NHMRC Senior Research Fellow, Level A 2008-2011 NHMRC Career Development Award, Level 2

of 26

2006 Harvard Stem Cell Institute Award for the poster presentation demonstrating the most promising research fulfilling the Harvard Stem Cell Institute’s objectives.

2002-2005 Translational Fellowship awarded by the Leukemia and Lymphoma Society of America 1999-2002 Special Fellowship awarded by the Leukemia and Lymphoma Society of America 1996 Certificate of Academic Achievement awarded by the National Australia Day Council,

January 26th. 1993-1994 Postgraduate Bursary awarded by The British Council, enabling 6 months PhD studies at the

Paterson Institute for Cancer Research, Manchester, UK in the laboratories of Professors Terry Allen and Mike Dexter

1991-1994 Australian Postgraduate Research Award, High Priority Area 1990-1994 Higher Education Contribution Scheme Exemption Scholarships 1990-1991 The Leslie Vacation Scholarship (Australian Cancer Society summer studentship) 1990 Anti-Cancer Council of Victoria Summer Studentship 1989-1990 R.D. Wright Summer Studentship EXTERNAL PEER REVIEWED FUNDED GRANTS Approximately $14.5 million in peer-reviewed funding to date including major equipment grant support. Current Research Support (approx. AUD $1.2 million) NHMRC Project Grant 01/01/19-31/12/21 Identifying therapies that accelerate blood cell recovery after cancer treatments. This study will determine how cancer therapies alter the bone marrow microenvironment support of blood cell production and seeks to identify new therapies to improve blood cell recovery in patients after cancer treatments. Role: CI-A The Cancer Council Victoria Grant-in-Aid 01/01/19-31/12/21 Identifying better therapies for blood cell cancers. This study will explore the effectiveness of FDA approved compounds that we have identified using a large scale chemical screen on MDS cells, with the aim to improve therapies for patients with MDS. Role: CI-A Completed Research Support (approx. $9.8 million to date, $7.7 million of which I was CI-A or sole CI) NHMRC Project Grant 01/01/17-31/12/19 Microenvironmental regulation of blood cells by retinoic acid receptor gamma. This study explored how retinoic acid receptor gamma extrinsically regulates haematopoiesis via microenvironment cells in the bone marrow and thymus. Role: CI-A The Cancer Council Victoria Grant-in-Aid 01/01/17-31/12/19 Structural linkage between ligand discrimination and receptor activation by interleukin-3. The goals of this study were to determine the mechanism by which interleukin-3 activates abnormal signaling in leukaemic cells. Role: CI-D. Zig Inge Foundation Project Grant 01/06/16-31/12/18 Improving blood stem cell transplantation This study investigated the potential of different vitamin A ligands to increase the numbers of blood-forming stem cells for transplantation purposes. Role: Sole CI The Cancer Council Victoria Grant-in-Aid 01/01/16-31/12/18 Impact of deregulated HOXA1 splicing in myelodysplastic syndromes. This study explored how deregulated HOXA1 contributes to myelodysplastic syndromes. Role: CI-A Catholic Archdiocese of Sydney Stem Cell Grant 01/01/13-31/12/15 Making umbilical cord blood stem cell transplants a reality for patients with blood cell diseases.

of 26

This study explored the use of retinoids to increase the numbers of umbilical cord blood-derived blood-forming cells for transplantation. Role: Sole CI. NHMRC Project Grant 01/01/13-31/12/15 Microenvironmentally Induced Acute Lymphoblastic Leukemia Cell Quiescence and Chemotherapy Evasion This study investigated the effects of the bone marrow microenvironment in regulating the ALL cells that relapse. Role: CI-B LEW Carty Charitable Fund 1/1/14-30/6/15 Making umbilical cord blood stem cell transplants a reality for patients with blood cell diseases. This supported my research on the potential of retinoids to increase the numbers of umbilical cord blood-derived stem cells for transplants. NHMRC Project Grant 01/01/11-31/12/13 Determining the impact of cytotoxic therapies on the bone marrow microenvironment. This study investigated the effects of chemotherapy and radiotherapy on the bone marrow microenvironment. Role: Sole CI NHMRC Senior Research Fellow, Level A 01/01/11-31/12/15 Regulation of haemopoiesis and bone by retinoids This fellowship investigated how retinoids regulate haematopoiesis and bone. Role: Sole CI (salary support only). Association for International Cancer Research Project Grant 01/06/10-31/5/13 Roles of the bone marrow microenvironment in haemopoietic diseases. This study investigated the nature of the bone marrow microenvironment cell types that contribute to haematopoietic diseases, and identified underlying mechanisms that contribute to these diseases. Role: Sole CI Leukaemia Foundation Grant-in-Aid 01/01/12-31/12/12 Involvement of HOXA1 in myeloid neoplasia. This study investigated the roles of HOXA1 in myelodysplastic syndromes. Role: CI-A The Cancer Council Victoria Grant-in-Aid 01/01/10-31/12/12 Roles of retinoic acid receptors in bone and haemopoiesis This study investigated the roles of retinoic acid receptors in regulating haemopoiesis and the bone marrow microenvironment. Role: CI-A Leukaemia Foundation Grant-in-Aid 01/01/10-31/12/10 Enhancing haematopoiesis after transplantation or chemotherapy. This study investigated how the bone marrow microenvironment responds to myeloablative therapies. Role: CI-A NHMRC Project Grant 01/01/08-31/12/10 Mechanisms underlying the effects of TNFalpha in bone and haemopoiesis. This study investigated the roles of TNFα in the haemopoietic and bone disease that occurs in a mouse model. Role: Sole CI Leukaemia Foundation Grant-in-aid 01/01/09-31/12/09 Roles of the Bone Marrow Microenvironment in Haematopoietic Disease This study investigated how the bone marrow microenvironment contributes to blood cell disease initiation and progression. Role: CI-A NHMRC Career Development Award, Level 2 01/02/08-31/12/10 Understanding how vitamin A deficiency affects bone and blood cell production. Fellowship (salary support only). I declined the final year of this 4 year grant due to being awarded an NHMRC SRF commencing in 2011.

of 26

Role: Sole CI NIH/NIDDK R21 Project Grant 05/05/06-30/04/09 Regulation of HSC self-renewal by morphogens This application investigated the interactions between morphogens known to regulate HSCs in both a context-dependent and context-independent manner with respect to the HSC niche. Role: Sole CI NHMRC Project Grant 01/01/05-31/12/07 Differentiation therapy of acute myeloid leukemia: combining RAR agonists and G-CSF. The major aims of this study were to investigate the therapeutic uses of combining RAR-specific agonists and G-CSF for differentiation therapy of acute myeloid leukaemia. Role: CI-B Leukemia and Lymphoma Society Translational Research Grant 01/09/04-31/08/07 The use of retinoids to mobilize hematopoietic stem cells for therapeutic purposes. This study involved Phase I and II clinical trials to evaluate the use of retinoids to enhance mobilization of haematopoietic stem cells. Role: CI-C The Cancer Council Victoria Grant-in-Aid 01/01/04-31/12/05 Use of retinoids and inhibitors of endothelial cell adhesion molecules to enhance mobilisation of haemopoietic stem cells by G-CSF. The major aims of this study were to investigate the potential of different molecules to enhance mobilisation of hematopoietic stem cells by G-CSF. Role: CI-B Leukemia and Lymphoma Society Translational Research Grant 01/09/02-31/08/05 The use of retinoids to expand hematopoietic stem cells for therapeutic purposes. The major aims of this study were to translate the effects of retinoids on murine HSCs into the human setting for therapeutic purposes. Role: CI-A NHMRC Project Grant 01/01/03-31/12/05 The roles of retinoids and their receptors in haemopoiesis. This study investigated the roles of retinoids and their receptors in murine hematopoiesis. Role: Sole CI The Cancer Council Victoria Grant-in-Aid 01/01/01-31/12/03 Enhancing ex vivo expansion of primitive haemopoietic progenitor cells by all-trans retinoic acid. The goals of this study were to explore the use of retinoids to expand murine and human hematopoietic stem cells. Role: CI-A Equipment Grants (approx $3.75 million to date) Wellcome Trust Major Equipment Grant 2003-2007 Flow cytometry facility for cancer research. This was to purchase an ARIA FACS-sorter and provide operator costs at Peter MacCallum Cancer Centre. Role: CI-E. ANZ Trustees-Medical Research and Technology in Victoria- William Buckland Foundation Grant 2008 Role of the bone marrow in blood diseases. This was to aid the purchase of a Sysmex KX-21 Haematological Analyser at SVI. Role: CI-A. Equity Trustees Cancer Research Trusts Small Project Grant 2009 Cutting edge technology for the imaging of blood and bone cancer progression in animal models of disease. This was to aid the purchase of a microCT at SVI. Role: Sole CI. The Potter Foundation Major Equipment Grant 2009-2010 The Bone and Blood Cancer Centre This equipment grant assisted in funding the purchase of a microCT, 17 colour FACS analyser and a GammaCell Exactor Irradiator to support the research being done at St. Vincent’s Institute.

of 26

Role: CI-A Australian Cancer Research Foundation Major Equipment Grant 2012 ACRF Rational Drug Discovery Centre This equipment grant assists in funding the purchase of a laser scanning cytometer and equipment for structural biology studies to support the research being done at St. Vincent’s Institute. Role: CI-B The Potter Foundation Major Equipment Grant 2013-2014 The Integrated Clinical Research Centre This equipment grant assisted in funding the purchase of a 6-way BD Influx sorter at SVI. Role: CI-B INTERNAL PEER REVIEWED FUNDED GRANTS St. Vincent’s Hospital Research Endowment Fund Seeding Grant for Research Project 01/01/2017-31/12/2017 The goals of this study were to perform a chemical screen to identify novel therapies for myelodysplastic syndromes. Role: CI-B St. Vincent’s Hospital Research Endowment Fund Seeding Grant for Research Project 01/01/2016-31/12/2016 The goals of this study were to optimise multi-colour immunofluorescence imaging for bone marrow biopsies. Role: CI-B INDUSTRY FUNDED GRANTS Allergan, Inc. Research Contract 01/05/02-31/04/04 Expansion of human hematopoietic cells using retinoids. The goals of this study were to investigate the effects of different retinoid ligands on human hematopoietic cells. Role: CI-A PROVISIONAL/PATENT APPLICATIONS None EDITORIAL/ REVIEWER ROLES Editorial Board member for the following journals: 2020- current Experimental Hematology (Associate Editor January 2020- ) 2018- current StemJournal (New journal established by the Harvard Stem Cell Institute to be launched in

in October 2018) (Associate Editor 2018-) 2017- current Experimental Hematology 2016- current Scientific Reports 2014- current PLoS One 2012-2015 F1000Research 2012-2014 Leukemia 2009-2015 Member, Faculty of 1000 Medicine, Hematopoiesis section REVIEWER FOR THE FOLLOWING JOURNALS / GRANTING AGENCIES Journals 1996- Ad-hoc reviewer for Blood 2002- Ad-hoc reviewer for Experimental Hematology 2003- Ad-hoc reviewer for the Journal of Cellular Physiology 2003- Ad-hoc reviewer for the International Journal of Biochemistry and Cell Biology 2007- Ad-hoc reviewer for FEBS Letters 2007- Ad-hoc reviewer for Stem Cells 2007- Ad-hoc reviewer for Cell Stem Cell 2008- Ad-hoc reviewer for Cell

of 26

2008- Ad-hoc reviewer for Acta Biochemica et Biophysica Sinica 2009- Ad-hoc reviewer for Bone 2009- Ad-hoc reviewer for Molecular Medicine 2009- Ad-hoc reviewer for EMBO Molecular Medicine 2009- Ad-hoc reviewer for Cell Death and Differentiation 2010- Ad-hoc reviewer for Journal of Bone and Mineral Research 2012- Ad-hoc reviewer for Molecular and Cellular Biology 2013- Ad-hoc reviewer for PLoS One 2014- Ad-hoc reviewer for Stem Cell Reports 2014- Ad-hoc reviewer for Stem Cell Research 2014- Ad-hoc reviewer for Nature Communications 2016- Ad-hoc reviewer for Journal of Clinical Investigation 2017- Ad-hoc reviewer for Developmental Biology 2017- Ad-hoc reviewer for Developmental Cell 2018- Ad-hoc reviewer for Bone Reports Grants 2001- 2018 Ad-hoc reviewer for NHMRC 2008-2015 Member, NHMRC Training Fellowships (Early Career Fellowships), Panel chair in 2015 2008 External grant reviewer for the Kay Kendall Leukaemia Fund, London, UK 2009 Member, Research Grant Committee, Leukaemia Foundation 2010-2011 Member, Fellowship Grant Committee, Leukaemia Foundation 2011 External reviewer, University of Leuven Senior Research Professor application 2012 Member, Grant Review Panel (GRP), NHMRC 2014 External grant reviewer, Melbourne Health Project Grants, Melbourne 2013 External reviewer, Research Foundation- Flanders (FWO) Postdoctoral Fellowship 2014- current External reviewer, Research Foundation- Flanders (FWO) Research Project 2015- current Member, Standing Research Subcommittee, Cancer Council Victoria 2016 External grant reviewer, KWF Kankerbestrijding (Dutch Cancer Society) 2015 External grant reviewer, Women’s and Children’s Hospital Foundation, Adelaide, Australia 2016 External grant reviewer, Singapore Ministry of Education 2018 Appointed to NHMRC GRP (withdrawn due to my cochlear implant procedure in August

2018) 2018 External grant reviewer, University of Leuven Junior Research Professor application 2019 External grant reviewer, Else Kröner Fresenius Stiftung, Germany 2019 External grant reviewer, National Science Center, Poland Abstract reviewer for the following Conferences 2008 50th Annual Meeting of the American Society of Hematology (ASH), San Francisco, USA. 2011 40th Annual Meeting of the International Society for Hematology (ISEH), Vancouver, Canada. 2012 New Directions in Leukaemia Research, Sunshine Coast, Qld, Australia. 2013 11th Annual Meeting of the International Society for Stem Cell Research (ISSCR), Boston, USA. 2013 42nd Annual Meeting of the ISEH, Vienna, Austria 2014 11th Annual Meeting of the ISSCR, Vancouver, Canada. 2014 New Directions in Leukaemia Research, Sunshine Coast, Qld, Australia. 2016 Annual Scientific Meeting of the Australasian Society for Stem Cell Research (ASSCR), Margaret

River, WA, Australia. 2017 14th Annual Meeting of the ISSCR, Boston, USA. 2017 46th Annual Meeting of the ISEH, Frankfurt, Germany. 2018 15th Annual Meeting of the ISSCR, Melbourne, Australia. 2019 16th Annual Meeting of the ISSCR, Los Angeles, USA. 2019 48th Annual Meeting of the ISEH, Brisbane, Australia. 2019 ASSCR-AGCTS-ISCT ANZ Joint Scientific Meeting, Brisbane, Qld. 2020 New Directions in Leukaemia Research, Brisbane, Qld, Australia. 2020 17th Annual Meeting of the ISSCR, Boston, USA.

of 26

TRAINEE SUPERVISION (Include College trainees) Undergraduate Students: Co-supervisor of Ms Yinan Zhang, ANU Medical School, for her MBBS Research Project (she obtained First Class Honours, 2010) Primary supervisor of the following 3rd year students in the course 536-304 Advanced Experimental Physiology through the Dept of Physiology, The University of Melbourne: Mr Samuel Lewis and Ms Heather Ford (2008), Ms Gabriella Farries and Mr Thomas Thiep Ngor (2009) Primary supervisor of the following 3rd year students in the course PATH30004 Advanced Investigation of Disease, Semester 2, The University of Melbourne: Ms Sarina Heng and Mr Steven Ngo (2011) Primary supervisor of Ms Stephanie Yanaputri, 3rd year student in the course BIOM30003 Biomedical Science Research project (Semester 1), The University of Melbourne (2012) Primary supervisor of Ms Abby McLean and Ms Nicole Day, 4th year students at RMIT for their Student Project, Semester 2 (2012) Primary supervisor of Mr Jake McNeil, 3rd year undergraduate student at Deakin University in the course SLE390 Professional Practice in Bioscience (2017). UROP Undergraduate student placements through The University of Melbourne: Co-supervisor of Ms Holly Brennan (2008-2009) Sole supervisor of Ms Hannah King (2011-2012) Summer Students: Supervisor of Mr Si Quang Vinh, Cancer Council Victoria Cancer Research Vacation Student (2001-2002) Co-supervisor of Mr Justin Chan, Cancer Council Victoria Cancer Research Vacation Student (2002-2003) Supervisor of Mr Camden Lo (2002-2003) Supervisor of Mr Ronald Hsu, summer student at the Center for Regenerative Medicine, Massachusetts General Hospital and Harvard University, Boston, USA (2005) Co-supervisor of Ms Carrie Tsang, Cancer Council Victoria Cancer Research Vacation Student (2010-2011). Co-supervisor of Ms Hannah King, Cancer Council Victoria Cancer Research Vacation Student (2011-2012). Supervisor of Mr Harvey Chong, SVI Summer Studentship (2015-2016). PhD SUPERVISION Current: Primary supervisor of Ms Clea Grace, PhD student through the Dept of Medicine, The University of Melbourne Co-primary supervisor of Dr ShuhYing Tan, PhD student through the Dept of Medicine, The University of Melbourne Co-supervisor of Dr Slavisa Ninkovic, PhD student through the Dept of Medicine, The University of Melbourne Completed: Primary basic science supervisor for Dr Kirsten Herbert, awarded her PhD through the Dept of Medicine, The University of Melbourne in 2007 Primary supervisor of Mr Chacko Joseph, awarded his PhD through the Dept of Medicine, The University of Melbourne in 2015 Co-supervisor of Ms Shreya Bhattacharya, awarded her PhD through the Dept of Medicine, The University of Melbourne in 2016 Primary supervisor of Ms Alanna Green, awarded her PhD through the Dept of Medicine, The University of Melbourne in 2016 DOCTOR OF MEDICINE SUPERVISION None MASTERS DEGREE SUPERVISION Masters of Biomedical Science, The University of Melbourne Completed: Primary supervisor of Ms Dana Alhuzaimi (2015-2016). Awarded 1st Class Honours. Primary supervisor of Ms Diannita Kwang (2017-2019). Awarded 1st Class Honours.

of 26

BACHELOR SCIENCE HONOURS STUDENT SUPERVISION Completed: Primary supervisor of Ms Celeste Nota, La Trobe University, 2009 (Celeste obtained First Class Honours and topped her year). Primary supervisor of Ms Alanna Green, Dept of Medicine, The University of Melbourne, 2010 (obtained 1st Class Honours, equal first in her year and was a recipient of a Dean’s Award from the Dean of Science, The University of Melbourne for her achievement). Co-supervisor of Ms Rachael Costanzo, La Trobe University, 2011 (Obtained 1st Class Honours). Primary supervisor of Ms Lenny Straszkowski, La Trobe University, 2013 (Obtained 1st Class Honours) Primary supervisor of Ms Amal Ghali, Dept of Medicine, The University of Melbourne, 2013 (Obtained 1st Class Honours). Co-supervisor of Ms Emma Lee, Dept of Pathology, The University of Melbourne, 2013 (Obtained 2nd Class Honours). Primary supervisor of Ms Victoria Ruldolph-Stringer, Department of Medicine, The University of Melbourne, 2015 (Obtained 1st Class Honours). Primary supervisor of Mr Jack O’Halloran, Department of Medicine, The University of Melbourne, 2015 (Obtained 1st Class Honours). ADVANCED MEDICAL SCIENCE (Scholarly Selective Students) SUPERVISION (Project title) None NATIONAL/ INTERNATIONAL TRAINING VISITORS Primary supervisor of Mr Emanuele Gioacchino, who undertook his 4 month Masters research project in my lab in late 2014, awarded his Masters Degree with First Class Honours in October 2015 (University of Rome Tor Vergata). Primary supervisor of Ms Maiko Kitaoka, Undergraduate student from MIT, Cambridge, USA under an MIT UROP program (Two months in June/July 2014). Co-supervisor of Ms Yinan Zhang, ANU Medical School, for her MBBS Research Project (she obtained First Class Honours), 2010. Co-supervisor of Ms Siebregje van Keulen, M.Sc. student from Wageningen University, Wageningen, The Netherlands, who spent 6 months in my lab at Peter MacCallum Cancer Centre for part of her degree (2002). PUBLICATIONS (List in reverse chronological order, most recent first) Books: Book Chapters: 1. Purton LE, Scadden DT (2009). Analysis of mouse hematopoietic stem and progenitor cells. In:

Methods in Bioengineering: Stem Cell Bioengineering, pp89-106. Artech House, B Parekkadan and ML Yarmush eds.

2. Collins S, Johnson B, Purton LE (2001). The role of retinoic acid receptors in myeloid differentiation. In: Transcription Factors: Normal and Malignant Development of Blood Cells. pp149-161. John Wiley and Sons, Ravid and Licht eds.

Manuscripts (Published or in press) 1. Nguyen CH, Bauer K, Hackl H, Schlerka A, Koller E, Hladik A, Stoiber D, Zuber J, Staber PB, Hoelbl-

Kovacic A, Purton LE, Grebien F, Wieser R. All-trans retinoic acid enhances, and a pan-RAR antagonist counteracts, the stem cell promoting activity of EVI1 in acute myeloid leukemia. Cell Death & Disease 2019 10:944.

2. Thai J, Green AC, Stamp LA, Spencer NJ, Purton LE, Ivanusic J. A population of non-neuronal GFRα3-expressing cells in bone marrow resembles non-myelinating Schwann cells. Cell and Tissue Research 2019 378:441-456.

3. Ku M, MacKinnon RN, Wall M, Narayan N, Walkley C, Cheng, HC, Campbell LJ, Purton LE*, Nandurkar H*. *Purton and Nandurkar are equal senior authors. Hemopoietic cell kinase amplification with protein tyrosine phosphatase receptor T depletion leads to polycythemia, aberrant marrow erythroid maturation and splenomegaly. Scientific Reports 2019 9:7050. (IF= 4.122)

4. Al-Sharea A, Lee MKS, Purton LE, Hawkins ED, Murphy AJ. The haematopoietic stem cell niche: A new player in cardiovascular disease? Cardiovasc Res 2019 115:277-291 (Invited Review).

of 26

5. Xu JJ, Smeets M, Tan SY, Wall M, Purton LE, Walkley CR. Modeling human RNA spliceosome mutations in the mouse: not all mice were created equal. Exp Hematol 2019 70:10-23. (IF= 2.436, citations= 0)

6. Tjin G*, Flores-Figueroa E*, Duarte D*, Straszkowski L, Scott M, Khorshed RA, Purton LE#, Lo Celso C#. Imaging methods used to study mouse and human HSC niches: current and emerging technologies. Bone 2019 119:19-35 (Invited review). *Tjin, Duarte and Flores-Figueroa are co-first authors, #Purton and Lo Celso are co-corresponding authors. (IF= 4.455, citations= 0)

7. Green AC*, Rudolph-Stringer V, Chantry AD, Wu JY*, Purton LE*. Mesenchymal lineage cells and their importance in B lymphocyte niches. Bone 2019 119:42-56 (Invited Review). *Green, Wu and Purton are co-corresponding authors. (IF= 4.455, citations= 3)

8. Martin SK, Fitter S, El Khawanky N, Grose RH, Walkley CR, Purton LE, Ruegg MA, Hall MN, Gronthos S, Zannettino ACW. mTORC1 plays an important role in osteoblastic regulation of B-lymphopoiesis. Scientific Reports 2018 8:14501. (IF= 4.122, citations= 0)

9. Joseph C*, Green AC*, Kwang D, Purton LE. Extrinsic regulation of hematopoietic stem cells and lymphocytes by vitamin A. Current Stem Cell Reports 2018 4:282-290. Invited review. *Joseph and Green are co-first authors. (New journal- no IF yet, citations= 0).

10. Green AC, Rudolph-Stringer V, Straszkowski L, Tjin G, Crimeen-Irwin B, Walia M, Martin TJ, Sims NA, Purton LE. Retinoic acid receptor γ activity in mesenchymal stem cells regulates endochondral bone, angiogenesis and B lymphopoiesis. JBMR 2018 33:2202-2213. (IF= 6.314, citations= 0)

11. Grace C, Mikkola HKA, Dou DR, Calvanese V, Ronn RE, Purton LE. Protagonist or antagonist? The complex roles of retinoids in the regulation of hematopoietic stem cells and their specification from pluripotent stem cells. Exp Hematol 2018 65:1-16 (Invited Review). (IF= 2.436, citations= 0)

12. Smeets MF, Tan SY, Xu JJ, Anande G, Unnikrishnan A, Chalk AM, Taylor SR, Pimanda JE, Wall M, Purton LE, Walkley CR. Srsf2P95H initiates myeloid bias and myelodysplastic/myeloproliferative syndrome (MDS/MPN) from hemopoietic stem cells. Blood 2018, 132:608-621. (IF= 15.132, citations= 0)

13. Duarte D, Hawkins ED, Akinduro O, Ang H, De Filippo K, Kong IY, Haltalli M, Ruivo N, Straszkowski L, Vervoort SJ, McLean C, Weber TS, Khorshed R, Pirillo C, Wei A, Ramasamy SK, Kusumbe AP, Duffy K, Adams RH, Purton LE, Carlin LM, Lo Celso C. Inhibition of endosteal vascular niche remodeling rescues hematopoietic stem cell loss in AML. Cell Stem Cell 2018, 22:64-77. (IF= 23.29, citations= 16)

14. Green AC, Kocovski P, Jovic T, Walia MK, Chandraratna RAS, Martin TJ, Baker EK, Purton LE. Retinoic acid receptor signaling directly regulates osteoblast and adipocyte differentiation from mesenchymal progenitor cells. Exp Cell Res 2017, 350:284-297. (IF= 3.309, citations= 9)

15. Hawkins ED, Duarte D, Akinduro O, Khorshed RA, Passaro D, Nowicka M, Straszkowski L, Scott MK, Rothery S, Ruivo N, Foster K, Waibel M, Johnstone RW, Harrison SJ, Westerman DA, Quach H, Gribben

J, Robinson MD§, Purton LE§, Bonnet D§, Lo Celso C. T-cell acute leukaemia exhibits dynamic interactions with bone marrow microenvironments. Nature 2016, 538:518-522. § Robinson, Purton and Bonnet are co-second last authors. (IF= 41.577, citations= 49)

16. Liddicoat BJ, Hartner JC, Piskol R, Ramaswami G, Chalk AM, Kingsley PD, Sankaran VG, Wall M, Purton LE, Seeburg PH, Palis J, Orkin SH, Lu J, Li JB, Walkley CR. Adenosine-to-inosine RNA editing by ADAR1 is essential for normal murine erythropoiesis. Exp Hematol 2016, 44:947-963. (IF= 2.436, citations= 6)

17. Chandrakanthan V, Yeola A, Kwan JC, Oliver RA, Qiao Q, Kang YC, Zarzour P, Beck D, Boelen L, Unnikrishnan A, Villanueva JE, Nunez AC, Knezevic K, Palu C, Nasrallah R, Carnell M, Macmillan A, Whan R, Yu Y, Hardy P, Grey ST, Gladbach A, Delerue F, Ittner L, Mobbs R, Walkley CR, Purton LE, Ward RL, Wong JW, Hesson LB, Walsh W, Pimanda JE. PDGF-AB and 5-Azacytidine induce conversion of somatic cells into tissue-regenerative multipotent stem cells. PNAS 2016, 113:E2306-15. (IF= 9.504, citations= 15)

18. Thoms JA, Knezevic K, Liu JJ, Glaros EN, Thai T, Qiao Q, Campbell H, Packham D, Huang Y, Papathanasiou P, Tunningley R, Whittle B, Yeung AW, Chandrakanthan V, Hesson L, Chen V, Wong JW, Purton LE, Ward RL, Thomas SR, Pimanda JE. Arrested hematopoiesis and vascular relaxation defects in mice with a mutation in Dhfr. Mol Cell Biol 2016, 36:1222-1236. (IF= 3.813, citations= 2)

19. Joseph C, Nota C, Fletcher JL, Maluenda AC, Green AC, Purton LE. Retinoic acid receptor γ regulates B and T lymphopoiesis via nestin-expressing cells in the bone marrow and thymic microenvironments. The Journal of Immunology 2016, 196:2132-2144. (IF= 5.185, citations= 4)

20. Bhattacharya S, Chalk AM, Ng AJM, Martin TJ, Zannettino AC, Purton LE, Lu J, Baker EK, Walkley CR. Increased miR-155-5p and reduced miR-148a-3p contribute to the suppression of osteosarcoma cell death. Oncogene 2016, 35:5282-5294. (IF= 6.854, citations= 17)

21. Tan SY, Smeets ME, Nandurkar H, Walkley CR, Purton LE, Wall M. Insights into myelodyspastic syndromes from current preclinical models. World Journal of Hematology 2016, 5:1-22 (Invited Review). (New online journal, no IF yet, citations= 0).

of 26

22. Green AC, Martin TJ, Purton LE. The role of vitamin A and retinoic acid receptor signaling in post-natal maintenance of bone. JSBMB 2016, 155:135-146. (IF= 4.095, citations= 17)

23. Askmyr M, White KE, Jovic T, King, HA, Quach JM, Maluenda AC, Baker EK, Smeets MF, Walkley CR, Purton LE. Ciliary neutrotrophic factor has intrinsic and extrinsic roles in regulating B cell differentiation and bone structure. Scientific Reports 2015, 5:15529. (IF= 4.122, citations= 4)

24. Nguyen, TM, Arthur A, Panagopoulos R, Paton S, Hayball JD, Zannettino ACW, Purton LE, Matsuo K, Gronthos, S. EphB4 expressing stromal cells exhibit an enhanced capacity for hematopoietic stem cell maintenance. Stem Cells 2015, 33:2838-2849. (IF= 5.587, citations= 12)

25. Green AC, Poulton IJ, Vrahnas C, Häusler KD, Walkley CR, Wu JY, Martin TJ, Gillespie MT, Chandraratna RAS, Quinn JMW*, Sims NA*, Purton LE*. RARγ is A Negative Regulator of Osteoclastogenesis. JSBMB 2015, 150:46-53. * Quinn, Sims and Purton are co-senior authors. (IF= 4.095, citations= 8)

26. Ng AJM, Walia MK, Smeets MF, Mutsaers AJ, Russell MR, Sims NA, Purton LE, Walsh NC, Martin TJ, Walkley CR. The DNA Helicase Recql4 is Required for Normal Osteoblast Expansion and Osteosarcoma Formation. PLoS Genetics 2015, 11:e1005160. (IF= 5.54, citations= 14)

27. Baker EK, Taylor S, Gupte A, Chalk AM, Battacharya S, Green AC, Martin TJ, Strbenac D, Robinson MD, Purton LE, Walkley CR. Wnt inhibitory factor 1 (WIF1) is a marker of osteoblastic differentiation stage and is not silenced by DNA methylation in osteosarcoma. Bone 2015, 73:223-232. (IF= 4.455, citations= 10)

28. Quach JM, Askymr M, Jovic T, Baker EK, Walsh NC, Harrison SJ, Neeson P, Ritchie D, Ebeling PR, Purton LE. Myelosuppressive therapies significantly increase pro-inflammatory cytokines and directly cause bone loss. JBMR 2015, 30:886-897. (IF= 6.314, citations= 14)

29. Smeets MF, DeLuca E, Wall M, Quach JM, Chalk AM, Deans AJ, Heierhorst J, Purton LE, Izon DJ, Walkley CR. The Rothmund-Thomson Syndrome helicase Recql4 is essential for hematopoiesis. J Clin Invest 2014, 124:3551-3565. (IF= 13.25, citations= 12)

30. Ku M, Wall M, Mackinnon RN, Walkley CR, Purton LE, Tam C, Izon D, Campbell L, Cheng HC, Nandurkar H. Src family kinases and their role in hematological malignancies. Leuk Lymph 2014, 5:1-20. (IF= 2.644, citations= 6)

31. Dewamitta S, Joseph C, Purton LE*, Walkley CR*. Erythroid-extrinsic regulation of normal erythropoiesis by retinoic acid receptors. Br J Haematol 2014, 164:280-285. *Purton and Walkley are equal senior authors. (IF= 5.128, citations= 7)

32. Noll JE, Williams SA, Tong CM, Wang, H, Quach JM, Purton LE, Pilkington K, To LB, Evdokiou A, Gronthos S, Zannettino AC. Myeloma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells. Haematologica 2014, 99: 163-171. (IF= 9.09, citations= 48)

33. Joseph C, Quach JM, Walkley CR, Lane SW, Lo Celso C, Purton LE. Deciphering hematopoietic stem cells in their niches: a critical appraisal of genetic models, lineage tracing, and imaging strategies. Cell Stem Cell 2013, 13:520-533 (Invited Review). (IF= 23.29, citations= 42)

34. Mutsaers AJ, Ng AJ, Baker EK, Russell MR, Chalk AM, Wall M, Liddicoat BJ, Ho PW, Slavin JL, Goradia A, Martin TJ, Purton LE, Dickins RA, Walkley CR. Modeling distinct osteosarcoma subtypes in vivo using Cre:low and lineage-restricted transgenic shRNA. Bone 2013, 55:166-178. (IF= 4.455, citations= 32)

35. Chee LC, Hendy J, Purton LE, McArthur GA. ATRA and the specific RARα agonist, NRX195183, have opposing effects on the clonogenicity of pre-leukemic murine AML1-ETO bone marrow cells. Leukemia 2013, 27:1369-1380. (IF= 10.023, citations= 7)

36. Chee LC, Hendy J, Purton LE*, McArthur GA*. The granulocyte-colony stimulating factor receptor (G-CSFR) interacts with retinoic acid receptors (RARs) in the regulation of myeloid differentiation. J Leukoc Biol 2013, 93:235-243. *Purton and McArthur are equal senior authors. (IF= 4.224, citations= 4)

37. Noll, JE, Williams, SA, Purton LE, Zannettino ACW. Tug of war in the haematopoietic stem cell niche: do myeloma plasma cells compete for the HSC niche? Blood Cancer Journal 2012, 2:e91; doi:10.1038/bcj.2012.38 (IF= 8.125, citations= 29)

38. Ohishi M, Ono W, Ono N, Khatri R, Marzia M, Baker EK, Root SH, Wilson TL, Iwamoto Y, Kronenberg HM, Aguila HL, Purton LE*, Schipani E*. A novel population of cells expressing both hematopoietic and mesenchymal markers is present in the normal adult bone marrow and is augmented in a murine model of marrow fibrosis. Am J Pathol 2012, 180:811-818. *Schipani and Purton are co-corresponding authors. (IF= 4.069, citations= 15)

39. Baker EK, Purton LE. A stressed niche not Wnted. Blood 2011 (Invited Inside Blood commentary) Blood 2011, 118:2377-2378. (IF= 15.132, citations= 0)

40. Wu JY, Aarnisalo P, Bastepe M, Sinha P, Fulzele K., Selig MK, Chen M, Poulton IJ, Purton LE, Sims NA, Weinstein LS, Kronenberg HM. Gsα enhances commitment of mesenchymal progenitors to the osteoblast lineage but restrains osteoblast differentiation in mice. J Clin Invest 2011, 121:3492-3504.

of 26

(IF= 13.25, citations= 50) 41. Walkley CR, Izon, DJ, Purton LE. Taking HSCs down a Notch in leukemia. Cell Stem Cell 2011, 8:602-

603 (Invited Preview). (IF= 23.29, citations= 1) 42. Singbrant S, Russell MR, Jovic T, Liddicoat B, Izon DJ, Purton LE, Sims NA, Martin TJ, Sankaran VG,

Walkley CR. Erythropoietin couples erythropoiesis, B lymphopoiesis, and bone homeostasis within the bone marrow microenvironment. Blood 2011, 117:5631-5642. (IF= 3.959, citations= 6)

43. Singbrant S, Askmyr M, Purton LE, Walkley CR. Defining the hematopoietic stem cell niche: The chicken and the egg conundrum. (Invited Review) J Cell Biochem. 2011, 112:1486-1490. (IF= 3.309, citations= 9)

44. Askmyr M, Quach J, Purton LE. Effects of the bone marrow microenvironment on hematopoietic malignancy. (Invited Review) Bone. 2011, 48:115-120. (IF= 4.455, citations= 19)

45. Guo S, Lu J, Schlanger R, Zhang H, Wang J, Fox M, Purton LE, Fleming H, Cobb B, Merkenschlager M, Golub T, Scadden DT. microRNA-125a controls hematopoietic stem cell number. PNAS 2010, 107:14229-14234. (IF= 9.504, citations= 211)

46. Askmyr M, Sims NA, Martin TJ, Purton LE. What is the true nature of the osteoblastic hematopoietic stem cell niche? (Invited Review) Trends in Endocrinology and Metabolism. 2009, 20:303-309. (IF= 10.769, citations= 58)

47. Wu JY*, Purton LE*, Rodda S, Chen M, Weinstein LS, McMahon AP, Scadden DT, Kronenberg HM. Osteoblastic regulation of B lymphopoiesis is mediated by Gsα-dependent signaling pathways. PNAS 2008, 105:16976-16981. *Wu and Purton are equal first authors. (IF= 9.504, citations= 127)

48. Purton LE, Scadden DT. The hematopoietic stem cell niche (November 15, 2008), StemBook, ed. The Stem Cell Research Community, StemBook, doi/10.3824/stembook.1.28.1, http://www.stembook.org. (Invited online book chapter, no IF and citations unable to be found in Scopus).

49. Kim WJ, Okimoto RA, Purton LE, Goodwin M, Haserlat SM, Dayyani F, Sweetser DA, McClatchey AI, Bernard OA, Look AT, Bell DW, Scadden DT, Haber DA. Mutations in the neutral sphingomyelinase gene SMPD3 implicate the ceramide pathway in human leukemias. Blood 2008, 111:4716-4722 (IF= 15.132, citations= 49)

50. Mukherjee S, Raje N, Schoonmaker JA, Liu JC, Hideshima T, Wein MN, Jones DC, Vallet S, Bouxsein ML, Pozzi S, Chhetri S, Seo YD, Aronson JP, Patel C, Fulciniti M, Purton LE, Glimcher LH, Lian JB, Stein G, Anderson KC, Scadden DT. Pharmacologic targeting of a stem/progenitor cell in vivo is associated with enhanced bone regeneration in mice. J Clin Invest 2008, 118:491-504 (IF= 13.25, citations= 178)

51. Ludlow LE, Purton LE, Klarmann K, Gough DJ, Hii LL, Trapani JA, Keller JR, Clarke CJP, Johnstone RW. The role of p202 in regulating hematopoietic cell proliferation and differentiation. J Interferon and Cytokine Research 2008 28:5-11. (IF 2.419, citations= 11)

52. Purton LE, Scadden DT. Limiting factors in murine hematopoietic stem cell assays. Cell Stem Cell 2007, 1:263-270 (Invited Review). (IF= 23.29, citations= 158)

53. Purton LE. Roles of retinoids and retinoic acid receptors in the regulation of hematopoietic stem cell self-renewal and differentiation. (Invited Review) PPAR Research 2007 (doi:10.1155/2007/87934). (IF= 3.386, citations= 17)

54. Walkley CR, Shea JM, Sims NA, Purton LE, Orkin SH. Rb regulates interactions between hematopoietic stem cells and their bone marrow microenvironment. Cell 2007, 129:1081-1095. (IF= 31.398, citations= 272)

55. Walkley CR, Olsen GH, Dworkin S, Fabb SA, Swann J, McArthur GA, Westmoreland SV, Chambon P, Scadden DT, Purton LE. A microenvironment-induced myeloproliferative syndrome caused by retinoic acid receptor γ deficiency. Cell 2007, 129:1097-1110. Walkley and Olsen are equal first authors. (IF= 31.398, citations= 313)

56. Herbert KE, Walkley CR, Winkler IG, Hendy J, Haines GH, Yuan YD, Chandraratna RAS, Prince HM, Levesque J-P*, Purton LE*. G-CSF and an RARα specific agonist, VTP195183, synergize to enhance the mobilization of hematopoietic progenitor cells. Transplantation 2007, 83:375-384. Purton and Levesque are equal senior authors. (IF= 3.96, citations= 19)

57. Purton LE, Scadden DT. Osteoclasts eat stem cells out of house and home. Nat Med 2006; 12:610-611. (IF= 32.621, citations= 18)

58. Purton LE, Dworkin S, Olsen GH, Walkley CR, Fabb SA, Collins SJ, Chambon P. RARγ is critical for maintaining a balance between hematopoietic stem cell self-renewal and differentiation. J Exp Med 2006; 203:1283-1293. (IF= 10.79, citations= 118)

59. Walkley CR, McArthur GA*, Purton LE*. Cell division and hematopoietic stem cells: not always exhausting. (Invited Review) Cell Cycle 2005; 4:893-896. *Purton and McArthur are equal senior authors. (IF= 3.304, citations= 11)

60. Walkley CR, Fero ML, Chien W-M, Purton LE*, McArthur GA*. Negative cell-cycle regulators cooperatively control self-renewal and differentiation of haematopoietic stem cells. Nat Cell Biol 2005; 7:172-178. *Purton and McArthur are equal senior authors. (IF= 19.064, citations= 85)

http://www.stembook.org/

of 26

61. Eto T, Winkler I, Purton LE*, Levesque J-P*. Contrasting effects of P-selectin and E-selectin on the differentiation of murine hematopoietic progenitor cells. Exp Hematol 2005; 33:232-242. *Purton and Levesque are equal senior authors. (IF= 2.436, citations= 18)

62. Frew IJ, Sims NA, Quinn JMW, Walkley CR, Purton LE, Bowtell DD, Gillespie MT. Osteopenia in Siah1a mutant mice. J Biol Chem 2004; 279:29583-29588. (IF= 4.01, citations= 6)

63. Walkley CR, Purton LE, Snelling HJ, Yuan YD, Nakajima H, Chambon P, Chandraratna RAS, McArthur GA. Identification of the molecular requirements for an RARα mediated cell cycle arrest during granulocytic differentiation. Blood 2004; 103:1286-1295. (IF= 15.132, citations= 29)

64. Frew IJ, Hammond VE, Dickins RA, Quinn JMW, Walkley CR, Sims NA, Schnall R, Della NG, Holloway AJ, Digby MR, Janes PW, Purton LE, Gillespie MT, Bowtell DD. Generation and analysis of Siah2 mutant mice. Mol Cell Biol 2003; 23:9150-9161. (IF= 3.813, citations= 51)

65. Anniss AM, Apostolopoulos J, Dworkin S, Purton LE, Sparrow RL. An oxysterol-binding protein family identified in the mouse. DNA and Cell Biology 2002; 21: 571-580. (IF= 2.634, citations= 44)

66. Purton LE, Morris JC, Bernstein ID, Collins SJ, Kiem H-P. All-trans retinoic acid facilitates oncoretrovirus-mediated transduction of hematopoietic repopulating stem cells. J Hematotherapy and Stem Cell Res. 2001; 10:815-825. (Journal discontinued in 2003, no IF due to this, citations= 1)

67. Collins SJ, Ulmer J, Purton LE, Darlington G. Multipotent hematopoietic cell lines derived from C/EBP{alpha}(-/-) knockout mice display granulocyte macrophage-colony-stimulating factor, granulocyte-colony-stimulating factor, and retinoic acid-induced granulocytic differentiation. Blood 2001; 98:2382-2388. (IF= 15.132, citations= 24)

68. Purton LE, Bernstein ID, Collins SJ. All-trans retinoic acid enhances the maintenance of long-term repopulating hematopoietic stem cells. Blood 2000; 95:470-477. (IF= 15.132, citations= 92)

69. Purton LE, Bernstein ID, Collins SJ. All-trans retinoic acid delays the differentiation of primitive hematopoietic precursors (lin- c-kit+ Sca-1+) while enhancing the terminal maturation of committed granulocyte/monocyte progenitors. Blood 1999; 94:483-495. (IF= 15.132, citations= 86)

70. Varnum-Finney B, Purton LE, Yu M, Brashem-Stein C, Flowers D, Staats S, Moore KA, Le Roux I, Mann R, Gray G, Artavanis-Tsakonas S, Bernstein ID. The Notch ligand, Jagged-1, influences the development of primitive hematopoietic precursor cells. Blood 1998; 91:4084-4091. (IF= 15.132, citations= 282)

71. Purton LE, Mielcarek M, Torok-Storb B. Monocytes are the likely candidate ‘stromal’ cell in G-CSF-mobilized peripheral blood. Bone Marrow Transplant. 1996; 21:1075-1076. (IF= 4.497, citations= 12)

72. Mielcarek M., Purton LE, Torok-Storb B. Accessory cell function may be retained in CD34-selected G-CSF-mobilized peripheral blood mononuclear cells. Br. J. Haematol. 1996; 93:495-497. (IF= 5.128, citations= 4)

73. Purton LE, Lee, MY, Torok-Storb B. Normal human peripheral blood mononuclear cells mobilized with granulocyte colony-stimulating factor have increased osteoclastogenic potential compared to nonmobilized blood. Blood 1996; 87:1802-1808. (IF= 15.132, citations= 51)

Publications as part of International study groups (Named as member of study group in publication) None Abstracts I have published numerous conference international and national abstracts since 1998, average of 4 per year. Institutional Publications I have been featured in a number of SVI newsletters and annual reports. INVITED PRESENTATIONS Completed 1993 Invited seminar: “The heterogeneity of bovine aortic endothelial cells.” Dept. of Anatomy, The

University of Basel, Basel, Switzerland, invited by Dr. Katherina Spanel-Borowski. 1993 Invited seminar: “The characterization of bone marrow endothelial cells.” Dept. of Surgery, Children’s

Hospital, Boston, MA, invited by Prof. Judah Folkman.

1993 Invited seminar: “The characterization of murine bone marrow stromal cells: a comparative study with bovine aortic endothelial cells and defined murine macrophage cells.” Dept. of Pathology, The University of Washington, Seattle, WA, invited by Prof. Norman Wolf.

of 26

1993 Invited seminar: “The characterization of murine bone marrow stromal cells: a comparative study with bovine aortic endothelial cells and defined murine macrophage cells.” Fred Hutchinson Cancer Research Center, Seattle, WA, invited by Prof. Beverly Torok-Storb.

1994 PhD completion seminar: “The characterization of murine bone marrow stromal cells: a comparative study with bovine aortic endothelial cells and defined murine macrophage cells.” Department of Physiology, The University of Melbourne, hosted by Dr Neil Williams.

1995 Invited seminar: “Osteoclastogenesis in cultures of G-CSF mobilized peripheral blood”. Fred Hutchinson Cancer Research Center Clinical Research Division Seminar Series, invited by Prof. Beverly Torok-Storb.

1996 Invited seminar: “Osteoclastogenesis in Cultures of G-CSF Mobilized Peripheral Blood.” AMGEN, Thousand Oaks, CA, USA, invited by Dr. Graham Molineux.

1996 Invited seminar: “Osteoclastogenesis in Cultures of G-CSF Mobilized Peripheral Blood.” Hanson Centre for Cancer Research, Adelaide, Australia, invited by Dr. Paul Simmons.

1996 Invited seminar: “Osteoclastogenesis in Cultures of G-CSF Mobilized Peripheral Blood.” St. Vincent’s Institute of Medical Research, Melbourne, Australia, invited by Dr. David Findlay.

2000 Invited seminar: “Pleiotropic Effects of All-Trans Retinoic Acid on Hematopoietic Stem and Progenitor Cells.” Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, USA, invited by Dr. Mervin Yoder.

2000 Invited seminar: “Pleiotropic Effects of All-Trans Retinoic Acid on Hematopoietic Stem and Progenitor Cells.” Terry Fox Laboratories, University of British Columbia, Vancouver, B.C., invited by Dr. Keith Humphries.

2000 Invited seminar: “Pleiotropic Effects of All-Trans Retinoic Acid on Hematopoietic Stem and Progenitor Cells.” Retinoid Research Team, Allergan Inc., Irvine, CA, USA, invited by Dr. Roshantha Chandraratna.

2000 Invited seminar: “Pleiotropic Effects of All-Trans Retinoic Acid on Hematopoietic Stem and Progenitor Cells.” Clinical Research Division Seminar Series, Fred Hutchinson Cancer Research Center, Seattle, WA, invited by Dr. Steven Collins.

2000 Invited seminar: “Pleiotropic Effects of All-Trans Retinoic Acid on Hematopoietic Stem and Progenitor Cells.” Dept. of Physiology, The University of Melbourne, Australia, invited by Dr. Neil Williams.

2000 Invited seminar: “Pleiotropic Effects of All-Trans Retinoic Acid on Hematopoietic Stem and Progenitor Cells.” Peter MacCallum Cancer Centre, Melbourne, Australia, invited by Dr. Paul Simmons.

2001 Invited seminar: “Pleiotropic Effects of All-Trans Retinoic Acid on Hematopoietic Stem and Progenitor Cells.” Queensland Institute of Medical Research, Brisbane, Australia, invited by Dr Chung Li.

2001 Invited seminar: “Mechanisms Underlying the Different Effects of All-Trans Retinoic Acid on Hematopoietic Stem and Progenitor Cells.” Retinoid Research Team, Allergan Inc., Irvine, CA, USA, invited by Dr. Roshantha Chandraratna.

2002 Invited seminar: “Distinct roles of retinoic acid receptors in haemopoiesis.” St. Vincent’s Institute for Medical Research, Melbourne, Australia, invited by Dr. Natalie Sims.

2002 Invited seminar: “Distinct roles of retinoic acid receptors in haemopoiesis.” Monash University, Melbourne, Australia, invited by Dr. Andrew Elefanty.

2002 Invited seminar: “Distinct roles of retinoic acid receptors in haemopoiesis.” The University of Melbourne and The Geelong Hospital Seminar Program, The Geelong Hospital, Australia, invited by Dr. Claudia Gregorio-King.

2002 Invited seminar: “Distinct roles of retinoic acid receptors in haemopoiesis.” Retinoid Research Team, Allergan Inc., Irvine, CA, USA, invited by Dr. Roshantha Chandraratna.

2003 Invited seminar: “A unique role for retinoic acid receptor gamma in the regulation of hematopoiesis.” Retinoid Research Team, Allergan Inc., Irvine, CA, USA, invited by Dr. Roshantha Chandraratna.

2003 Invited seminar: “A unique role for retinoic acid receptor gamma in the regulation of hematopoiesis.” Center for Regenerative Medicine and Technology, Massachusetts General Hospital, Boston, MA, USA, invited by Prof David Scadden.

of 26

2004 Invited conference oral presentation: “Retinoic acid receptor gamma is a key regulator of haemopoietic stem cells”, 16th Lorne Cancer Conference, Lorne, Australia.

2004 Invited presentation: “The use of retinoids to expand hematopoietic stem cells for therapeutic purposes.” Annual meeting of the Leukemia and Lymphoma Society, New York, USA.

2004 Invited seminar: “Retinoic acid receptor gamma is a key regulator of haemopoietic stem cells.” The Samuel Bronfman Department of Medicine, Mt Sinai School of Medicine, New York, NY, USA, invited by Dr Doris Germain

2005 Invited seminar: “Retinoic acid receptor gamma: A master regulator of haemopoiesis.” Mater Medical Research Institute, Brisbane, Australia, invited by Dr Jean-Pierre Levesque.

2005 Invited presentation: “Retinoic acid receptor gamma: a critical regulator of stem cells.” Harvard Stem Cell Institute internal meeting, Boston, USA.

2006 Invited seminar: “A Microenvironment-induced Myeloproliferative Syndrome Caused by RARγ Deficiency.” New England Primate Research Center, Southborough, MA, USA, invited by Dr Susan Westmoreland.

2007 Invited symposium presentation: “A novel role for the hematopoietic microenvironment in initiating and sustaining hematopoietic disease.” Gene Expression Systems Symposium: Stem Cells and Regenerative Medicine, San Francisco, USA.

2007 Invited symposium presentation: “Regulation of haemopoiesis by retinoic acid receptor gamma”. Mater Medical Research’s 4th Stem Cell Symposium, Brisbane, Australia.

2007 Invited seminar: “Regulation of haemopoiesis by retinoic acid receptor gamma”. St. Vincent’s Institute for Medical Research, Melbourne, Australia, invited by Prof Tom Kay.

2007 Invited conference presentation: “Understanding the relationship between bone, haematopoiesis and disease”. Gordon Conference: Bones and Teeth, Biddeford, ME, USA.

2007 Invited plenary speaker in the Plenary Session II: Stem Cell Niches, 36th Annual meeting of the International Society for Experimental Hematology (ISEH), Hamburg, Germany (declined due to the birth of my first child).

2008 Invited conference presentation: “The bone microenvironment and myeloproliferative disease.” 18th Annual Scientific Meeting of the Australian and New Zealand Bone and Mineral Society, Melbourne, Australia.

2008 Invited conference presentation 2008 FASEB Summer Research Conference on Retinoids, New Haven, CT, USA. Declined due to care of young child.

2008 Invited seminar: “Regulation of haematopoietic stem cells and their microenvironment.” The Hanson Centre for Cancer Research seminar series, invited by Profs Andrew Zannettino and Stan Gronthos.

2008 Invited seminar: “Regulation of haematopoietic stem cells and their microenvironment.” Fred Hutchinson Cancer Research Center, invited by Prof Steven Collins.

2009 Invited conference presentation: “The bone microenvironment and myeloproliferative disease.” VIII International Meeting on Cancer Induced Bone Disease, Sydney, Australia.

2009 Invited seminar: “Blood cell production: why your daily dose of Vitamin A is important for you.” SVI Seminar series.

2009 Invited seminar: “Understanding the relationship between bone, blood and stem cells.” RMIT Seminar series, invited by Dr Janine Danks.

2009 Invited seminar: “Targeting the bone marrow microenvironment to treat hematopoietic diseases.” Clinical Research Division Seminar Series, Fred Hutchinson Cancer Center, invited by Prof Beverly Torok-Storb.

2009 Invited seminar: “Targeting the bone marrow microenvironment to treat hematopoietic diseases.” Vanderbilt Centre for Bone Biology, Nashville, TN, USA, invited by Prof Greg Mundy.

2010 Invited conference presentation, New Directions in Leukaemia Research, Sunshine Coast, Australia (declined due to the birth of my second child).

2010: Invited conference presentation: “Regulation of hematopoietic stem cells by retinoic acid receptors.” 2010 FASEB Summer Research Conference on Retinoids, Phoenix, AZ, USA.

2010 Invited seminar: “Myeloablative therapies damage and alter the composition of the cells of the bone marrow microenvironment.” Seminar series, Australian Centre for Blood Cell Diseases.

of 26

2011 Invited symposium presentation: “Regulation of hematopoiesis by the bone marrow microenvironment.” International Symposium on Stem Cells and Regenerative Medicine, organised by the Mexican Group for Stem Cell Research, Mexico City, Mexico.

2012 Invited conference presentation: “Novel mouse model of MDS based on altered splicing expression of Hoxa1.” New Directions in Leukaemia Research, Sunshine Coast, Qld, Australia.

2012 Invited Grand Rounds presentation: “Acute leukaemia and retinoids; clinic and lab. Lab-based research on retinoids in haematopoiesis.” Grand rounds, St. Vincent’s Hospital, Melbourne (joint presentation with Prof Harshal Nandurkar).

2012 Invited seminar: “Regulation of haematopoiesis by the bone marrow microenvironment.” Seminar series, Victorian Institute of Forensic Medicine, invited by Dr Irene Kourtis.

2012 Invited seminar: “Identifying intrinsic and extrinsic regulators of HSCs and their resulting therapies.” Essen University Institute for Transfusion Medicine Seminar Series, Essen, Germany, invited by Prof Peter Horn.

2012 Invited seminar: “Impact of cancer therapies on the bone marrow microenvironment.” Seminar series, Lund Stem Cell Center, Lund University, invited by Prof Stefan Karlsson.

2012 Invited seminar: “Identifying intrinsic and extrinsic regulators of HSCs and their resulting therapies.” Seminar series, Department of Medicine, Karolinska Institute, Stockholm, Sweden, invited by Prof Eva Hellstrom-Lindberg.

2012 Invited conference presentation: “Cytotoxic therapies significantly alter the composition of the cells comprising murine hematopoietic stem cell niches.” The Australian Health and Medical Research Congress and Australiasian Society for Stem Cell Research joint session, Adelaide, Australia.

2013 Invited seminar: “The impact of cancer therapies on cells comprising HSC niches.” Seminar series, Skeletal Biology and Engineering Center, KU Leuven, Leuven, Belgium, invited by Dr Christa Maes.

2013 Invited Grand Rounds presentation: “The impact of cancer therapies on cells comprising HSC niches.” Grand Rounds, Endocrine Division, Stanford University, invited by Dr Joy Wu.

2014 Invited conference presentation: “Modeling myelodysplastic syndromes in mice by altered Hoxa1 spliceform expression.” 26th Lorne Cancer Conference, Lorne, Australia.

2014 Invited seminar: “The impact of cancer therapies on cells comprising haematopoietic stem cell niches.” Seminar series, Peter MacCallum Cancer Centre, Melbourne, Australia, invited by Dr Jane Oliaro.

2014 Invited seminar: “Intrinsic and extrinsic regulation of haematopoiesis by retinoic acid receptor gamma.” Seminar series, Australian Centre for Blood Cell Diseases, Mlebourne, Australia, invited by Dr Mark Guthridge.

2014 Invited seminar: “Modeling myelodysplastic syndromes in mice by altered Hoxa1 spliceform expression.” Seminar series, Monash Haematology, Monash University, Melbourne, Australia, invited by Dr George Grigoriadis.

2014 Invited seminar: “The impact of cancer therapies on cells comprising haematopoietic stem cell niches.” Seminar series, Austin Haematology, Austin Hospital, Melbourne, Australia, invited by Dr Carole Smith.

2014 Invited seminar: “The impact of cancer therapies on cells comprising haematopoietic stem cell niches.” SVI seminar series.

2014 Invited seminar: “The impact of cancer therapies on cells comprising haematopoietic stem cell niches.” Seminar series and part of the Women in Science program of the Mechanobiology Institute, National University of Singapore, Singapore, invited by Dr Rishita Changede. My talk was followed by a half hour discussion about my experiences being a woman in science.

2014 Invited conference presentation: “Modeling myelodysplastic syndromes in mice by altered Hoxa1 spliceform expression.” International Society for Stem Cell Research (ISSCR) Global Controls in Stem Cells conference, co-organised by the ISSCR and Stem Cell Society Singapore, Singapore. I was one of two Australian invited speakers at this conference.

2015 Invited conference presentation, Pathology Update 2015 (Melbourne, Australia). Declined due to Keystone Symposium invitation (same dates).

2015 Invited conference presentation: “Cytotoxic therapies cause irreversible damage to the niches for multipotent progenitor cells.” Keystone Symposium on Hematopoiesis, Keystone, Colorado, USA. I was the only Australian invited speaker at this conference.

of 26

2015 Invited seminar: “Regulation of haematopoiesis by microenvironment cells.” Postgraduate students seminar series, WEHI, Melbourne, Australia. Invited by Dr Matthew McCormack.

2015 Invited seminar: “Regulation of haematopoiesis by microenvironment cells.” Department of Anatomy and Neuroscience, The University of Melbourne, invited by Dr Jason Ivanusic.

2015 Invited conference presentation: “Cytotoxic therapies cause irreversible damage to the niches for multipotent progenitor cells resulting in impaired long-term repopulating potential of bone marrow.” Presented in the HSC Niche- ISEH/Japanese Society of Hematology joint session. 45th annual meeting of the International Society for Experimental Hematology, Kyoto, Japan.

2015 Invited conference presentation, ComBio Australia (declined due to overlap in timing of the ISEH presentation).

2015 Invited seminar: “Cytotoxic therapies cause irreversible changes to bone marrow microenvironments.” The Baker IDI Institute, Melbourne, Australia, invited by Dr Andrew Murphy.

2016 Invited conference presentation: “Cytotoxic therapies permanently alter microenvironmental support of HSCs and progenitors.” New Directions in Leukaemia Research, Sunshine Coast, Australia.

2017 Invited plenary speaker: “The impact of cancer therapies on bone marrow microenvironments and their regulation of haematopoiesis.” Australian Society for Medical Research, South Australia Annual Scientific Meeting.

2017 Invited seminar: “Altered expression of Hoxa1 isoforms perturbs haematopoiesis and is sufficient to induce myelodysplasia.” Haematology and Oncology Seminar Series, Mie University Hospital, Tsu, Mie, Japan. Invited by Professor Kohshi Ohishi.

2018 Invited conference presentation: “My career path.” This was a half hour presentation in the Gender Equity session at the 2018 New Directions in Leukaemia Research conference, Brisbane, Australia.

2018 Invited seminar: “Regulation of haematopoiesis by vitamin A.” WEHI postgraduate students seminar series, invited by Dr Leigh Coultas.

2018 Invited seminar: “Key roles of Hoxa1 in haematopoiesis and myelodysplastic syndromes.” WEHI Molecular Medicine seminar, invited by Dr Samir Taoudi.

2018 Invited seminar: “Bone marrow microenvironments: the factories for blood cell production.” Victorian Cancer Comprehensive Centre (VCCC) Comprehensive Cancer PhD Program seminar series, invited by Dr Erika Cretney.

2019 Invited seminar: “Key roles of Hoxa1 in HSCs and myelodysplastic syndromes”. Presented at Stem Cell Technologies, Vancouver, BC, Canada, invited by Dr Allen Eaves.

2019 Invited seminar: “Key roles of Hoxa1 in HSCs and myelodysplastic syndromes”. Presented at British Columbia Cancer Research Centre, Vancouver, BC, Canada, Vancouver, BC, invited by Prof Connie Eaves.

2019: Invited conference presentation, “Retinoic acid receptor gamma activity in distinct MSCs differentially regulates B and T lymphocyte production”. Presented in the Plenary 6 Satellite Session: MSCs as Therapeutic Targets at the 25th Annual Scientific Meeting of the International Society of Cell and Gene Therapy, Melbourne, May-June 2019.

2019 Invited conference presentation, “Key roles of Hoxa1 in HSCs and myelodysplastic syndromes”. Presented in the HSC Biology session at the annual meeting of the International Society for Experimental Hematology, Brisbane.

2019 Invited Keynote Speaker, “Key roles of Hoxa1 in HSCs and myelodysplastic syndromes”. Presented at “Blood in Brain- 2019 Conference on Research and Therapy to Extramedullary Hematopoiesis and Malignancies” Shanghai, China, organised by Professor Tong Chen, Department of Haematology, Fudan University, Shanghai, China.

2019 Invited conference presentation, “Key roles of Hoxa1 in myelodysplastic syndromes”. Presented in the Transcription Factors session at the Myeloid Biology workshop at the annual meeting of the American Society of Hematology, Orlando, USA.

A recent career disruption and its impact on invited presentations: From July 2018 I declined all invitations to present seminars for the remainder of the year due to having a cochlear implant (and the time taken to adjust to this procedure). I had been invited by A/Prof Nikki Verrills to present at the Hunter Medical Research Institute, Newcastle, NSW and by Prof Jean-Pierre Levesque to

of 26

present at the Mater Medical Research Institute, Translational Research Institute, The University of Queensland.

Chair/Moderator at National/International Conferences 2018 Co-chair, Stem Cells session, New Directions in Leukaemia Research (NDLR), Brisbane, Qld,

Australia. 2016 Co-chair, New Investigator session, NDLR, Noosa, Qld, Australia. 2016 Invited judge for the best oral presentation, The University of Melbourne Medical and Dental Health

Sciences Early Career Researcher Network Symposium 2014 Co-chair, Gender Equity session, NDLR, Noosa, Qld, Australia. 2014 Co-chair, New Investigator session, NDLR, Noosa, Qld, Australia. 2013 Co-chair, Lineage Specification II session, 42nd Annual meeting of the International Society of

Hematology (ISEH), Vienna, Austria. 2013 Panel member, New Investigator session on Effective Networking, 42nd Annual Meeting of the ISEH,

Vienna, Austria. 2010 Co-chair, Osteoimmunology session, Annual meeting of the Australian and New Zealand Bone and

Mineral Society (ANZBMS), Adelaide, Australia. 2008 Co-chair, Microenvironment session, Annual meeting of the American Society for Hematology

(ASH), San Francisco, USA. BOARDS: 2015-2017 Member, Scientific Advisory Board, Regen BioPharma, Inc., La Mesa, CA, USA (I voluntarily

resigned from this Board) 2010-2013 Member, Board of Directors, International Society of Hematology (ISEH). COMMITTEES: International 2017-2020 Member, ASH Scientific Committee on Stem Cells and Regenerative Medicine. 2014-2016 Member, Awards Committee, ISEH (comprising two consecutive terms). 2012-2013 Member, Nominating Committee, ISEH. National 2019-2020 Member, Scientific Organising Committee, New Directions in Leukaemia Research 2020

Symposium (Brisbane, March 20202). 2017-2018 Member, Organising Committee, New Directions in Leukaemia Research Symposium (for

the 2018 conference). 2015-2016 Member, Organising Committee, New Directions in Leukaemia Research Symposium (for

the 2016 conference). 2014-current Member, Executive Committee, New Directions in Leukaemia Research Symposium. 2013-2014 Member, Scientific Organising Committee, New Directions in Leukaemia Research 2014

Symposium (Sunshine Coast, March 2014). 2011-2012 Member, Scientific Organising Committee, New Directions in Leukaemia Research 2012

Symposium (Sunshine Coast, March 2012). State 2015- current Member, Standing Research Subcommittee, Cancer Council of Victoria Local 2014-current Member, Faculty of Medicine, Dentistry and Health Sciences Graduate Research

Committee, The University of Melbourne 2011-2019 Founder and Member, St. Vincent’s Institute of Medical Research Career Development

Committee 2010- 2019 Associate Director, St. Vincent’s Institute of Medical Research 2010- 2019 Member, Faculty Executive, St. Vincent’s Institute of Medical Research 2010- 2019 Member, St. Vincent’s Academic Centre Research Training Committee, Department of

Medicine, The University of Melbourne 2008-2012 Member, St. Vincent’s Health Animal Ethics Committee 2001-2004 Member, Peter MacCallum Cancer Centre PhD supervisory committee 1997 Co-organiser of the Interdisciplinary Cancer Course, Fred Hutchinson Cancer Reseach

Center. This course was organised to give staff at FHCRC an overview of cancer and

of 26

processes involved in initiating cancer, comprising lectures from members of all Divisions of the FHCRC.

1996-2000 Founding member, Fred Hutchinson Cancer Research Center Interdisciplinary Club for post-doctoral fellows and students. This was an informal meeting organised to encourage interdisciplinary research exchange between post-doctoral fellows and students from the different Research Divisions at the Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

CURRENT MAJOR RESEARCH THEMES: I am a basic researcher with a passion for translational research. The majority of my studies are designed with the goal of translating my findings into the clinic, and I collaborate with clinicians in Australia and overseas to achieve these goals. To date, four clinical trials have been designed based on my basic research, these are overviewed in the Current Clinical Activities section further below. My basic research themes are detailed below. The regulation of haematopoietic stem cell self-renewal by retinoic acid receptors. My research has pioneered studies exploring the role of vitamin A, its biologically active ligands and its receptors (retinoic acid receptors, RARs) in haematopoiesis and I am internationally recognised as a leading investigator in this field. My studies have shown that the RARs have different, and at times opposing, roles in regulating haematopoiesis. During my postdoctoral studies I discovered that the naturally occurring biological derivative of vitamin A, all-trans retinoic acid (ATRA) is a key regulator of the self-renewal of haematopoietic stem cells (HSCs). Since my postdoctoral studies I have significantly expanded this research and have shown that RARγ is essential for HSC self-renewal, whereas RARα has major roles in enhancing the differentiation of HSCs. We have also shown that some types of leukaemia cells that do not differentiate in response to ATRA do differentiate in response to an RARα specific agonist. This research has implications for cell therapies such as increasing the numbers of HSCs for transplantation purposes. It has also led to a current clinical trial in the USA to investigate the therapeutic use of an RARα specific agonist in the treatment of some leukaemias (see Current Clinical Activities section below). Current research in this theme involves the identification of how the different RARs have distinct roles in regulating haematopoiesis, and the use of RAR-specific ligands to expand HSCs and progenitor cells for therapeutic purposes. My retinoid research has also involved investigations of the effects of RARs on the bone marrow microenvironment, discussed in the next theme. Extrinsic regulation of haematopoiesis by the bone marrow microenvironment. The non-blood forming cells (including bone-forming cells, fat and blood vessels) that are contained in bone marrow help to regulate the production of different blood cells and are collectively termed bone marrow microenvironment cells. Identifying the nature of different bone marrow microenvironment cells was the primary goal of my PhD studies, at a time when little was known about the bone marrow microenvironment. My senior author Cell paper in 2007 revealed novel roles of the bone marrow microenvironment in initiating and sustaining blood cell diseases. I am internationally recognised as an expert in bone marrow microenvironment studies. My current studies that are examining the roles of these cells in the regulation of haematopoiesis have largely focused on two separate areas: 1) the roles of RARs in regulating haematopoiesis via bone marrow microenvironment cells and 2) the effects of cancer therapies on the bone marrow microenvironment and the consequences on haematopoiesis. My studies are using different transgenic mouse models, innovative imaging methods and various assays of bone and haematopoietic cells. The use of mouse models of myelodysplastic syndromes (MDS) to understand MDS and identify better therapies for MDS. Myelodysplastic syndromes are heterogeneous pre-leukaemic blood cell diseases, of which 30% of patients spontaneously progress to leukaemia. There are limited treatment options for MDS, and the only current chance of a cure (allogeneic bone marrow transplant) is not an option for the majority of patients due to their advanced age at diagnosis. My laboratory has developed novel models of MDS based on altered expression of two forms of the Hoxa1 protein, which we have found to be significantly deregulated in human MDS immature bone marrow cells. We have shown that these mouse models (retroviral and conditional knock-in models) faithfully represent MDS and that some of the mouse models progress to leukaemia. We are using these models to better understand MDS, and also to identify novel therapies for MDS. The use of advanced imaging technologies to study blood cell diseases using patient bone marrow biopsies. A limitation in studying rare human diseases is the amount of patient tissue available for study, and the technologies that are available to utilise these tissues. My laboratory has been optimising the use of a novel multiplexing technology, OpalTM Multiplex Immunohistochemistry, which is enabling us to examine up to 10 different antigens on a single section at the same time. We have recently published using this technology to

of 26

study mouse bone marrow sections. We are now optimising the use of this to study changes in bone marrow cell populations in patient bone marrow biopsies in collaboration with Associate Professor Hang Quach, St. Vincent’s Hospital, which forms part of a clinical trial discussed further below. TEACHING/MEDICAL EDUCATION: I have been a primary supervisor of 7 Honours students (all obtained 1st Class Honours, two topped their year, one was a recipient of a Dean’s Award from the Dean of Science, The University of Melbourne). I was a secondary supervisor of an additional Honours student who obtained 2nd Class Honours. I have been a primary supervisor of two Masters students at The University of Melbourne (1 current, the other obtained 1st Class Honours). I have supervised three PhD students to completion and am the current primary/co-primary supervisor of two PhD students and co-supervisor of another PhD student. I have also been the primary supervisor of 21 undergraduate students (including third year research course work, UROP placements and summer studentships) and hosted two international Masters students in my laboratory for their research projects (both obtained 1st Class Honours). All of my PhD students have received notable awards and achievements during their PhD studies. These are summarised for my three completed PhD students below. Dr Kirsten Herbert was awarded the Leukaemia Foundation Max Whiteside Clinical Fellowship, the Leukaemia Foundation of Victoria AMP Clinical Fellowship and a Haematology Society of Australasia and New Zealand (HSANZ) Scholarship during her PhD studies. She was also awarded the HSANZ Baikie Medal (for the most promising New Investigator) in 2005. Kirsten received the inaugural Cancer Council Victoria Early Career Clinical Research Fellowship (2008-2011). Dr Herbert is now a Consultant Haematologist at Cabrini and Peter MacCallum Cancer Centre and co-heads the Blood Unit at the Cabrini Hospital. Dr Chacko Joseph was an inaugural recipient of the Victorian Comprehensive Cancer Centre (VCCC) 2013 PhD Student Prize. He was a recipient of an SVI Foundation PhD Award (top-up stipend provided only to the most outstanding students) and was also a recipient of an abstract achievement award from the American Society of Hematology (ASH) and a travel grant from Eastern Hill Academic Centre, The University of Melbourne. Chacko is now an Associate Commercialisation Manager at Monash Innovation, Monash University. Dr Alanna Green was awarded the Dean’s Award from the Dean of Science, The University of Melbourne for her Honours degree. She was also awarded Junior Investigator of the Year, St. Vincent’s Hospital, Melbourne for an oral presentation based on her Honours project. She was a recipient of an SVI Foundation PhD Award and received numerous New Investigator Travel Awards (American Society of Bone and Mineral Research, FASEB Retinoids conference, Cancer Therapeutics and Eastern Hill Academic Centre, The University of Melbourne). Alanna was a recipient of The University of Melbourne’s Overseas Research Experience Scholarship (enabling 3 months study in Dr Andy Chantry’s laboratory at The University of Sheffield, UK during her PhD). She is currently a postdoctoral fellow in Dr Andy Chantry’s laboratory in the Sheffield Myeloma Research Team at The University of Sheffield, UK. 2016- current The University of Melbourne, EDUC20069 Deafness and Communication: Since 2016 I have also been a guest lecturer invited to present annually to students undertaking the University of Melbourne’s Deafness and Communication subject. 2013- current Masters of Clinical Audiology, The University of Melbourne: Since 2013 I have been a regular guest lecturer to students undertaking the University of Melbourne’s Masters of Clinical Audiology course, where I speak about my experiences as a hearing impaired person. This usually amounts to one lecture per year, however in 2018 I presented twice, once prior to having a cochlear implant and the second presentation was one month after having my cochlear implant switched on. MENTORSHIP: I am an advocate for supporting the career development of all investigators, and I am particularly proactive in supporting women in science. I initiated the Gender Equity session at the biannual New Directions in Leukaemia Research (NDLR) conference in 2014, and it is now a regular session at this meeting. At the Gender Equity session in 2016, we generated a document providing guidelines on supporting Women in Science. This document was circulated to all participants and their Institutes, and was also provided to the NHMRC. I also initiated the “Meet the Expert” breakfast at NDLR in 2014, which has become a very popular ongoing feature for new investigators attending the meeting. I have continued to assist most of my former students and employees in their career choices, and actively mentor numerous other researchers who have never been a member of my laboratory. The following researchers are current mentees of mine, with whom I am in regular correspondence either by e-mail (for mentees who are based interstate or overseas) or in person (mentees based in Melbourne).

of 26

2019- current Dr Gabriela Brumatti, WEHI I have known Gabi for a number of years due to being an advisor of her PhD student. In 2019 I formalised a mentorship arrangement with her. She is a current recipient of a VCA Mid-career Fellowship. 2018- current Ms Christina Nelson. Christina worked in my lab as a research assistant for 4 months prior to undertaking her Honours year in Biochemistry at Monash University. I have been actively mentoring her since late 2018. She was a Laboratory Technician at Albert Park College from 2018-2019 and is currently preparing to return to studies. 2018- current Dr Nisha Narayan, Murdoch Children’s Research Institute I have known Nisha since she was a research assistant in Prof Harshal Nandurkar’s laboratory in the Dept of Medicine, St. Vincent’s Hospital (2009-2012). She left in 2012 and undertook PhD studies with A/Prof Paul Ekert at WEHI and MCRI, completing her PhD studies in 2016. I formally became her mentor in early 2018. Nisha is now undertaking a postdoctoral fellowship with Prof Brian Huntly at the Cambridge Institute for Medical Research, UK. 2018- current Dr Jess Holien, St. Vincent’s Institute of Medical Research Jess is an Early-Mid Career Researcher at SVI. Although I have informally mentored her since we met in 2009, I officially became her mentor in 2018. She was the inaugural 5point Foundation Christine Martin Fellow and is transitioning into an independent researcher position at SVI under my mentorship and supervision. 2016- current Dr Gemma Kelly, WEHI Gemma and I co-organised the NDLR Gender Equity session in 2016 and I have mentored her since. She was a senior post-doctoral fellow at WEHI (Prof Andreas Strasser’s lab) and became a lab Head at WEHI in July, 2019. Gemma is a current recipient of a VCA Mid-career Fellowship. 2016- current Dr Catherine Carmichael, Australian Centre for Blood Cell Diseases (ACBD) I met Catherine when she was a postdoctoral scientist at WEHI, and have mentored her since she moved to ACBD in 2016. She became a group leader at ACBD in December 2019. 2016- current Dr Charlotte Hodson, Astex Pharmaceuticals (UK). I commenced mentoring Charlotte when she was a postdoctoral fellow at SVI and met with her regularly during this time. She returned to the UK in 2017 to take up a position in industry. We remain in contact via e-mail. 2014- current Dr Thao Nguyen, Centre for Cancer Biology, University of South Australia, Adelaide I have mentored Thao since she was a PhD student in the laboratory of one of my collaborators, Prof Stan Gronthos. We are in regular e-mail correspondence. Thao is now an NHMRC ECF based in Prof Stuart Pitson’s laboratory in Adelaide. 2014- current Dr Ain Roesley, Victorian Clinical Genetics Services, Melbourne, Australia I have mentored Ain since she was a PhD student at SVI. We meet regularly in person to discuss her career progression. 2013- current Associate Professor Hang Quach, Dept of Haematology, St. Vincent’s Hospital, Melbourne. Hang and I have actively collaborated since 2013 and I have also become a mentor to her during this period. She is the current recipient of the VCA Mid-Career Clinical Fellowship and is the Director of Haematology at St. Vincent’s Hospital, Melbourne. 2013- current Assistant Professor Satish Khurana, Indian Institute of Science Education and Research (IISER), Thiruvananthapuram. I met Satish when he was a postdoctoral fellow in the laboratory of Dr Catherine Verfaillie, KU Leuven, Belgium. Since then we have corresponded by e-mail about research projects and I also provided him with

of 26

advice when he was seeking his independent lab position in India. He is currently a Wellcome trust-DBT India alliance fellow heading his own lab at IISER. 2010- current Dr Kim Rice, Scientific Alliance Manger, Phylogica Limited, Perth, Western Australia I met Kim when she was a postdoctoral fellow in the laboratory of Prof Jon Licht. We discussed her returning to my lab to undertake a postdoctoral fellowship but she instead went to France for personal reasons (her partner was French) and undertook a second post-doc with Prof Hugues de Thé. Kim moved into industry and is the mother of two young children, which has restricted her return to academia, which she is keen to do. In 2017 she and her family moved to Perth, Western Australia. We keep in contact by e-mail and I also involve her in intellectual contribution to some of my research, in order to maintain her publications in academia so that she will have a smoother transition into an academic position when she is ready to return to research. 2008- current Dr Maria Askmyr, Alligator Biosciences. Maria was my first postdoctoral fellow at St. Vincent’s Institute. She returned to Sweden after two very successful years in my laboratory. Maria recently transitioned into an industry position and since March 2018 she has been employed at Alligator Biosciences, Sweden. 2007- current Dr Eugenia Flores-Figueroa, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada. I met Eugenia at a small conference at the beginning of 2007 and have mentored her since. Until late 2018 she headed her own laboratory in Mexico, but recently moved to Toronto, Canada, where she accepted a position as lab manager in Dr Faiyaz Notta’s laboratory, Princess Margaret Cancer Centre, University Health Network, Toronto. 2006- current Dr Cristina Lo Celso, Imperial College, London, UK. I have known Cris since she was a postdoctoral fellow in Prof David Scadden’s lab, where I was a visiting scientist from 2004-2007. I have been in regular correspondence with her since leaving Boston, and have advised her on her career development throughout this period, especially since she started her own lab in 2009. We also actively collaborate. CURRENT CLINICAL ACTIVITIES: I am a basic researcher with a passion for translational research and I actively collaborate with clinicians in Melbourne and Sydney. My research is contributing to a current clinical trial: ACTRN12615000818538, “Single arm, multicentre study evaluating the safety and efficacy of Carfilzomib in combination with Thalidomide and Dexamethasone (CaTD) in patients with relapsed and/or refractory multiple myeloma (RRMM)”. This trial is being led by one of my clinical collaborators, Associate Professor Hang Quach, a clinical researcher at St. Vincent’s Hospital and Department of Medicine, St. Vincent’s Hospital, Melbourne. In addition, the following clinical trials have arisen as a direct consequence of my translational research program: Clinical trial currently in force: NCT02749708, Study of IRX5183 in relapsed and refractory acute myeloid leukemia and high risk myelodysplastic syndrome. This project is being led by Dr Richard Jones at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA. This trial will explore the usefulness of an RAR alpha agonist to treat patients with acute myeloid leukaemia and myelodysplastic syndromes. This trial is based on results from my co-author 2013 publication in Leukemia and on my hypothesis that the RARs have different effects on haematopoietic cells. Clinical trial discontinued due to lack of patient recruitment: NCT02451462, Trial of zoledronic acid to prevent bone loss in hematopoietic cell transplant recipients. PI Dr Joy Wu, Stanford University, CA, USA. The goal of this trial was to determine the effectiveness of zoledronic acid to prevent the bone loss commonly observed in transplant recipients, with zoledronic acid administered prior to bone marrow transplant. This trial was entirely based on my 2015 JBMR senior author publication. Completed clinical trials: NCT00400556, ATRA plus G-CSF for mobilization of hematopoietic stem and progenitor cells. PI Dr Kirsten Herbert, Peter MacCallum Cancer Centre, Melbourne, Vic., Australia. This Phase I trial investigated the potential of ATRA and G-CSF to mobilize hematopoietic stem and progenitor cells in 6 patients with lymphoma and multiple myeloma. It was entirely based on my 2007 Transplantation co-senior author paper.

of 26

The results of this trial were reported in Herbert et al., Bone Marrow Transplantation 40: 801-803, 2007. NCT00234169, A phase I/II study of peripheral blood progenitor cells mobilisation with VTP195183 plus granulocyte-colony stimulating factor (G-CSF) compared to mobilisation with G-CSF alone in patients with multiple myeloma and lymphoma. PI Dr Kirsten Herbert, Peter MacCallum Cancer Centre, Melbourne, Vic., Australia. This trial was also entirely based on my 2007 Transplantation co-senior author paper. ADDITIONAL TRAINING: (e.g. accreditation courses, management, media or supervisor training) 2017 Marlow Hampshire Victorian Medical Research Institute Leadership Development Course

(sponsored by St. Vincent’s Institute of Medical Research) 2017 Victorian Comprehensive Cancer Centre (VCCC) Leadership Development Program by the

Melbourne Business School (I was invited to apply and sponsored by the VCCC to undertake this leadership program).

MEDIA EXPERIENCE The two Cell papers I published in 2007 gained widespread media attention online and were also the subject of a published article in the Herald Sun, 1st July 2007. My research was used to appeal for funding to purchase new equipment for the research at SVI in an article published in The Age on 13th August 2009. An article overviewing my research on the use of vitamin A ligands to increase the numbers of blood-forming stem cells to improve umbilical cord blood transplants were the basis of an article published in numerous sources online (medical writer Michelle Henderson, initially published on news.com.au on 31st January 2013 and thereafter it was published in numerous online sources internationally). I was featured in an article in the Herald Sun on March 11th 2013 to announce the award of an ACRF major equipment grant to SVI (grant recipients Prof Michael Parker, Dr Carl Walkley and myself). I have also been involved in a number of videos developed for SVI, and I was asked to represent medical research recipients of grants from the Ian Potter Foundation in a video presentation that formed part of their 2012-2013 annual grant report. In 2017 I was asked to be the Ambassador for Philanthropy (nominated by the Leukaemia Foundation) and was filmed for an advertisement that was screened on SBS and online social media sources (Facebook, Pinterest, etc) in April 2017 to promote the Holden + SBS “How will you drive change?” campaign. See http://holden.sbs.com.au/ambassador/louise and https://vimeo.com/203206493 PUBLIC PRESENTATIONS 1996 Invited speaker, “Stem Cell Mobilisation”, Swan Hill Australian Red Cross Blood Service, Swan Hill,

Vic., Australia. 2005 Panellist member, “Growing new body parts”, Museum of Science Public Outreach Forum on Tissue

Engineering, Boston, MA, USA 2008- I regularly give lab tours at SVI to members of the public 2008 Invited speaker, Sunbury Probus Club, Victoria, Australia 2009 Invited speaker, Cancer Connect (a public symposium jointly held by the Cancer Council of Victoria

and the Leukaemia Foundation), Melbourne 2010 Invited speaker, National Myeloma Day function held by the Leukaemia Foundation, Melbourne 2013 Invited speaker, Vermont Cancer Research Fundraising Group, Melbourne 2014 Invited speaker at the Glenroy Lion’s Club Girls’ Night In fundraiser 2014 My laboratory hosted the inaugural Victorian tour for the Leukaemia Foundation’s National MDS Day 2016 Invited speaker, Vermont Cancer Research Fundraising Group, Melbourne 2016 I was interviewed about my career path at the school assembly at Grace Lutheran College, Rothwell

Campus (senior school), Redcliffe, Qld, after which I also had a round table discussion with a selection of year 12 students interested in STEM careers.

2018 Invited speaker at the Susan Alberti Foundation’s Mother’s Day luncheon, Leonda by the Yarra, Melbourne, where I spoke about the challenges associated with being a woman in research

http://holden.sbs.com.au/ambassador/louise

of 26

PREVIOUS EMPLOYMENT HISTORY 1995-1996 Postdoctoral fellow in the laboratory of Dr. Beverly Torok-Storb, Fred Hutchinson Cancer

Research Center, Seattle, WA. 1996-2000 Postdoctoral fellow in the laboratories of Dr. Steven Collins and Irwin Bernstein, Fred

Hutchinson Cancer Research Center, Seattle, WA 2000-2004 Senior Research Officer, Peter MacCallum Cancer Centre, Melbourne, Vic., Australia 2004-2005 Research Associate, Peter MacCallum Cancer Centre, Australia 2004-2007 Visiting Scientist, Assistant in Biology, Massachusetts General Hospital, Boston, USA 2004-2007 Instructor, Department of Medicine, Harvard University, Boston, USA 2006-2007 Affiliated Faculty Member, Harvard Stem Cell Institute, Boston, USA

major achievements and summary · major achievements and summary . publications. top 3 papers based...

Documents